Abstracts tagged "registry"

Abstract Number: 1465 • ACR Convergence 2020
The Impact of the Combined Vaccination Scheme Against Streptococcus Pneumoniae on the Incidence of Related Infections in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARD: Data from BIOBADASER 3.0
Sebastian Rodriguez-Garcia¹, Carlos Sanchez-Piedra², Raul Castellanos-Moreira³, Dolores Ruiz-Montesinos⁴, Victoria Hernandez⁵, Manuel Pombo-Suarez⁶, Fernando Sanchez-Alonso², Loreto Carmona⁷ and JJ Gómez-Reino⁸, ¹La Princesa University Hospital, Madrid, Spain, ²Biobadaser, Research Unit, Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Clinic of Barcelona, Barcelona, Spain, ⁴Hospital Virgen Macarena, Sevilla, Spain, ⁵Hospital Clínic Barcelona, Barcelona, Spain, ⁶Hospital Clínico de Santiago, Santiago de Compostela, Spain, ⁷Instituto de Salud Musculoesquelética, Madrid, Spain, ⁸IDIS-CHUS - Rheumatology Group, Santiago de Compostela, Spain
Background/Purpose: Respiratory infections are among the leading causes of hospitalization in rheumatoid arthritis (RA) and Streptococcus Pneumoniae (SP) is one of the most frequent pathogens…
Abstract Number: 0012 • ACR Convergence 2020
Experiences of Patients with Rheumatic Diseases in the US During the Early Months of the COVID-19 Pandemic
Kristin Wipfler¹, Yomei Shaw², Teresa Simon³, Adam Cornish¹, Bryant England⁴, Alexis Ogdie⁵, Patricia Katz⁶ and Kaleb Michaud⁴, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, East Lansing, MI, ³Bristol-Myers Squibb Company (at time of analysis), Princeton, NJ, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Pennsylvania, Philadelphia, PA, ⁶University of California, San Francisco, Novato, CA
Background/Purpose: Patients with rheumatic diseases such as RA and lupus have increased risk of infection and are treated with medications that may increase this risk…
Abstract Number: 0824 • ACR Convergence 2020
The Comparative Effectiveness of Abatacept versus Tofacitinib After 6 Months of Treatment in Patients with RA Who Were Anti-citrullinated Protein Antibody Positive at Baseline: Results from a US National Observational Study
Leslie Harrold¹, Keith Wittstock², Sheila Kelly², Xue Han², Ying Shan¹, Page Moore¹, Lin Guo¹ and Vadim Khaychuk², ¹Corrona, LLC, Waltham, MA, ²Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: Previous data from the Corrona RA registry, conducted in a US clinical practice setting, demonstrated that patients (pts) with RA who were ACPA+ had…
Abstract Number: 1479 • ACR Convergence 2020
Long-Term Effectiveness of Canakinumab in Autoinflammatory Diseases – Interim Analysis of the CAPS Subgroup from the RELIANCE Registry
Jasmin Kuemmerle-Deschner¹, Birgit Kortus-Goetze², Michael Borte³, Ivan Foeldvari⁴, Gerd Horneff⁵, Ales Janda⁶, Tilmann Kallinich⁷, Prasad T. Oommen⁸, Catharina Schuetz⁹, Frank Weller-Heinemann¹⁰, Julia Weber-Arden¹¹ and Norbert Blank¹², ¹University Hospital Tuebingen, Tuebingen, Germany, ²Division of Nephrology, University of Marburg, Germany, Marburg, Germany, ³ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, ⁴Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Department of Pediatrics, University Hospital Ulm, Germany, Ulm, Germany, ⁷Charite, Berlin, Germany, ⁸Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁹Department of Pediatric Immunology, University Hospital Dresden, Dresden, Germany, Dresden, Germany, ¹⁰Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, ¹¹Novartis Pharma GmbH, Nuremberg, Germany, ¹²Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany
Background/Purpose: In the treatment of monogenic autoinflammatory diseases (AID), a heterogeneous group of diseases with excessive interleukin (IL)-1β release and severe systemic and organ inflammation,…
Abstract Number: 0058 • ACR Convergence 2020
Drug Retention and Discontinuation of Biological DMARDs and Novel Small Molecules: Data from the Singapore National Biologics Registry
Li Wearn Koh¹, Man Hua Aw², Preeti Dhanasekaran³, Rosa Lim Mui San¹, Stephanie Wong⁴, Xanthe Chua⁵, Wei Joo Choy¹, Manjari Lahiri⁶ and Siaw Ing Yeo², ¹Tan Tock Seng Hospital, Singapore, Singapore, ²Singapore General Hospital, Singapore, Singapore, ³National University of Singapore, Singapore, Singapore, ⁴Clinical Research and Innovation Office, Tan Tock Seng Hospital Singapore, Singapore, Singapore, ⁵Tan Tock Seng Hospital, Singapore, Singapore, Singapore, ⁶National University Hospital, Singapore, Singapore
Background/Purpose: To describe drug retention rate and reasons for discontinuation of biological disease modifying anti-rheumatic drugs ( bDMARD) and novel small molecules in patients from…
Abstract Number: 0829 • ACR Convergence 2020
International Comparison of Japanese and US Cross Country Utilization of RA Medications
Hisashi Yamanaka¹, Mitsumasa Kishimoto², Kazuhisa Nakano³, Kenta Misaki⁴, Yuji Yamanishi⁵, Hiroaki Dobashi⁶, Masamitsu Natsumeda⁷, Toshiaki Miyamoto⁸, Koichi Amano⁹, Akira Sagawa¹⁰, Norihiko Koido¹¹, Corrona Japan Consortium¹², Leslie Harrold¹³, Tin-chi Lin¹³, Jeffrey Greenberg¹⁴ and Yoshiya Tanaka³, ¹Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, ²Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Kitaharima Medical Center, Ono, Japan, ⁵Hiroshima Rheumatology Clinic, Hiroshima, Japan, ⁶Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ⁷Mabi Memorial Hospital, Kurashiki, Japan, ⁸Seirei Hamamatsu General Hospital, Hamamatsu, Japan, ⁹Saitama Medical Center, Kawagoe, Japan, ¹⁰Sagawa Akira Rheumatology Clinic, Sapporo, Japan, ¹¹Kawasaki RA & IM Clinic, Kawasaki, Japan, ¹²Corrona Japan Consortium, Japan, Japan, ¹³Corrona, LLC, Waltham, MA, ¹⁴Corrona, LLC and NYU School of Medicine, Waltham, MA
Background/Purpose: Little is known regarding differences in DMARD utilization across countries. A better understanding is needed to contextualize findings from different countries.1 Using the same…
Abstract Number: 1632 • ACR Convergence 2020
Long-Term Efficacy and Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – First Interim Analysis of the FMF-TRAPS-HIDS/MKD Subgroup of the RELIANCE Registry
Joerg Henes¹, Norbert Blank², Michael Borte³, Ivan Foeldvari⁴, Gerd Horneff⁵, Markus Hufnagel⁶, Tilmann Kallinich⁷, Birgit Kortus-Goetze⁸, Catharina Schuetz⁹, Frank Weller-Heinemann¹⁰, Julia Weber-Arden¹¹ and Jasmin Kuemmerle-Deschner¹², ¹Department of Internal Medicine II, Rheumatology, University Hospital Tuebingen, Germany, Tuebingen, Germany, ²Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany, ³ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, ⁴Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center, Medical Faculty, University of Freiburg, Germany, Freiburg, Germany, ⁷Charite, Berlin, Germany, ⁸Division of Nephrology, University of Marburg, Germany, Marburg, Germany, ⁹Department of Pediatric Immunology, University Hospital Dresden, Dresden, Germany, Dresden, Germany, ¹⁰Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, ¹¹Novartis Pharma GmbH, Nuremberg, Germany, ¹²University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Autoinflammatory periodic fever syndromes characterized by excessive interleukin(IL)-1ß release and severe systemic and organ inflammation have been successfully treated with the anti-IL-1ß inhibitor canakinumab.…
Abstract Number: 0178 • ACR Convergence 2020
Associations of Multimorbidity with DMARD Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness (RISE) Registry
Bryant England¹, Huifeng Yun², Lang Chen³, Kaleb Michaud¹, Ted Mikuls¹ and Jeffrey R Curtis², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Although a treat-to-target strategy is endorsed in rheumatoid arthritis (RA) treatment guidelines, its routine implementation in real-world settings, particularly in the context of multimorbidity,…
Abstract Number: 0834 • ACR Convergence 2020
Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry
Stefano Fiore¹, Lang Chen², Cassie Clinton², Huifeng Yun², Amy Praestgaard³, Kerri Ford³ and Jeffrey R Curtis², ¹Sanofi, Bridgewater, NJ, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Sanofi, Cambridge, MA
Background/Purpose: Patients with RA who have received multiple biologics or targeted therapies over time tend to have more refractory and more severe disease, which may…
Abstract Number: 1665 • ACR Convergence 2020
Sociodemographic and Clinical Predictors of Childhood-Onset SLE Disease Activity in the Childhood Arthritis and Rheumatology Research Alliance Registry
Emily Smitherman¹, Rouba Chahine¹, Timothy Beukelman¹, Andrea Knight², AKM Rahman¹, Mary Beth Son³, Jeffrey R Curtis⁴ and Aimee Hersh⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³Boston Children's Hospital, Boston, MA, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Utah and Primary Children's Hospital, Salt Lake City
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) are at high risk for early morbidity and mortality, but predictors of moderate/high cSLE disease activity have…
Abstract Number: 0183 • ACR Convergence 2020
Incidence of Malignancies in Japanese Patients with Rheumatoid Arthritis: Data from a Large Japanese National Registry
Toshihiro Matsui¹, Naonobu Sugiyama², Tsutomu Kawaguchi², Aosa Kamezaki², Shigeyuki Toyoizumi³, Fujio Matsuyama⁴, Tatsunori Murata⁴, Yukitomo Urata⁵, Kimito Kawahata⁶ and Shigeto Tohma⁷, ¹Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan, ²Pfizer Japan Inc, Tokyo, Japan, ³Pfizer R&D Japan G.K., Tokyo, Japan, ⁴CRECON Medical Assessment Inc, Tokyo, Japan, ⁵Department of Rheumatology, Tsugaru General Hospital, Aomori, Japan, ⁶Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁷National Hospital Organization Tokyo National Hospital, Tokyo, Japan
Background/Purpose: Patients (pts) with RA have an increased risk of some malignancies compared with the general population, and this can vary by region/race.1,2 Epidemiologic data…
Abstract Number: 0873 • ACR Convergence 2020
Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arthritis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip Mease¹, Robert McLean², Taylor Blachley², Laura Anatale-Tardiff³, Christopher Saffore⁴, Charlie Lovan⁵ and Alexis Ogdie⁶, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Waltham, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc., North Chicago, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: When deciding to start patients with PsA on biologic therapy, rheumatologists may focus on skin involvement in addition to joint symptoms. The purpose of…
Abstract Number: 1673 • ACR Convergence 2020
Principles of Pediatric Lupus Nephritis in a Contemporary Multi-Center Cohort
Kathleen Vazzana¹, Ankana Daga², Beatrice Goilav³, Ekemini Ogbu⁴, Daryl Okamura⁵, Catherine Park⁶, Rebecca Sadun⁷, Emily Smitherman⁸, Brian Stotter⁹, Scott Wenderfer¹⁰ and Laura Lewandowski¹¹, ¹National Institute of Health/Children's National Hospital, Washington, DC, ²Harvard, Boston, MA, ³The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Seattle's Children's, Seattle, WA, ⁶Emory University, Atlanta, GA, ⁷Duke University, Durham, NC, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Washington University School of Medicine, St. Louis, MO, ¹⁰Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, ¹¹NIAMS, NIH, Rockville, MD
Background/Purpose: Lupus nephritis (LN) is a well-established and life-threatening manifestation of systemic lupus erythematosus (SLE) that is more common in children than adults. The demographics…
Abstract Number: 0306 • ACR Convergence 2020
Characteristics of Patients with Early Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Taylor Blachley², Kelechi Emeanuru², Sven Richter³, Benoit Guerette³ and Philip Mease⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Amgen Inc., Thousand Oaks, ⁴Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: The efficacy of apremilast vs placebo for the treatment of oligoarticular PsA of ≤2 years duration is being investigated in the FOREMOST trial (NCT03747939).…
Abstract Number: 0879 • ACR Convergence 2020
Application of Treat-to-Target in Axial Spondyloarthritis in Daily Practice
Esther Beckers¹, Annelies Boonen¹, Casper Webers¹, Peter Ten Klooster², Harald Vonkeman², Monique Efde³ and Astrid van Tubergen⁴, ¹Maastricht University Medical Center, Maastricht, Netherlands, ²University of Twente, Enschede, Netherlands, ³VieCuri Medical Center, Venlo, Netherlands, ⁴Maastricht University Medical Center, Maastricht
Background/Purpose: Treat-to-target (T2T) management strategies in inflammatory rheumatic diseases aim to prevent damage and improve overall functioning and health by treating patients towards a predefined…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].